Product Images Doxazosin

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 4 images provide visual information about the product associated with Doxazosin NDC 51655-206 by Northwind Pharmaceuticals, Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Label - 51655 206 52 Rev A 04 23

Label - 51655 206 52   Rev A 04 23

Doxazosin is a prescription drug available in tablet form. Each tablet contains 1mg of Doxazosin Mesylate and is packaged in a container with 30 tablets. The pill is only available via prescription and should be stored in its original container at controlled room temperature, 15°-30°C (59°-86°F). The drug should be kept out of children's reach. The UPC code is 00351655206522, and the lot number is 0000000000. This drug was repackaged by Northwind Pharmaceuticals from Upsher-Smith Laboratories in Indianapolis. Please check the package insert for dosage information.*

Chemical Structure - doxazosin 01

Chemical Structure - doxazosin 01

Table 3 - doxazosin 02

Table 3 - doxazosin 02

This is a table that shows the results of three studies related to doxazosin and placebo. The studies involve patients with BPH (benign prostatic hyperplasia) and hypertensives. The studies aim to measure the maximum flow rate, symptom score, and the efficacy phase of doxazosin compared to placebo. The table presents information such as the baseline, mean, and mean change of the parameters measured in each study. The modifications made to the questionnaires used to obtain the symptom score are also specified. A total of 36 patients received a dose of 8 mg doxazosin. The text includes statistical p-values that compare the results of doxazosin and placebo for each study.*

Figure 1 - doxazosin 03

Figure 1 - doxazosin 03

This is a figure presenting data from a study regarding the change in total symptom score and maximum urinary flow rate in patients undergoing treatment for an unspecified condition. The figure shows a graph with the duration of treatment (in weeks) on the x-axis and the mean increase in maximum urinary flow rate (measured in mL/sec from baseline) and change in total symptom score on the y-axis. The data in the graph was collected from a sample size of 47 participants. Results indicate that treatment was beneficial compared to placebo and baseline, with statistical significance values indicated. No information is provided regarding the specifics of the treatment or condition being studied.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.